SCHEMBL30860892

SCHEMBL30860892

Cn1ncc2c(Nc3ncc(C(F)(F)F)c(NC4CC4)n3)cccc21

nearest known ligand 0.61

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 13/20 0.61
LRRK2 Q5S007 5/20 0.55
CHEK1 O14757 2/20 0.54
FLT3 P36888 2/20 0.54
ULK2 Q8IYT8 3/20 0.53
CYP1A2 P05177 1/20 0.48
AURKA O14965 1/20 0.48
NTRK1 P04629 1/20 0.48
CDK1 P06493 1/20 0.48
IGF1R P08069 1/20 0.48
KIT P10721 1/20 0.48
EPHA1 P21709 1/20 0.48
CDK2 P24941 1/20 0.48
BMX P51813 1/20 0.48
JAK3 P52333 1/20 0.48
CDK6 Q00534 1/20 0.48
PAK1 Q13153 1/20 0.48
ALK Q9UM73 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27228251 1.00 ULK1 (0.61) ULK1LRRK2CHEK1FLT3ULK2
SCHEMBL30860886 0.88 ULK1 (0.59) ULK1LRRK2CHEK1FLT3ULK2
SCHEMBL30860900 0.88 ULK1 (0.61) ULK1LRRK2ULK2
SCHEMBL27228032 0.87 ULK1 (0.58) ULK1LRRK2CHEK1FLT3ULK2
SCHEMBL30860934 0.87 ULK1 (0.58) ULK1LRRK2CHEK1FLT3ULK2
SCHEMBL30860992 0.87 ULK1 (0.58) ULK1LRRK2CHEK1FLT3ULK2
SCHEMBL27227885 0.87 ULK1 (0.58) ULK1LRRK2CHEK1FLT3ULK2
SCHEMBL30860971 0.86 LRRK2 (0.65) ULK1LRRK2CYP1A2
SCHEMBL27228000 0.86 LRRK2 (0.65) ULK1LRRK2CYP1A2
SCHEMBL30860816 0.86 ULK1 (0.56) ULK1LRRK2CHEK1FLT3ULK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. 2024-05-30 US disclosed
WO-2024073073-A2 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240174647-A1 KINASE MODULATORS AND METHODS OF USE THEREOF LRRK2, MAP3K20, MAP3K5 ULK1 138/4885LRRK2 1/4885CHEK1 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.